To bring next-generation immunotherapies for multiple myeloma and B cell disorders to market that will transform outcomes by prolonging survival while preserving quality of life for patients worldwide.
To redefine the standard of care, establishing a new treatment paradigm for haematological cancers and B cell disorders.
We are committed to delivering meaningful outcomes that matter to patients.
We advance science that improves and extends lives, guided by intellectual and scientific curiosity.
We uphold the highest ethical standards in everything we do, staying genuine in our intent to serve patients.
We relentlessly pursue high-impact, data-driven therapies.
Driven by a shared vision, we foster team solidarity and build global partnerships to accelerate progress.
On the basis of outstanding clinical results, we strive to generate robust, sustainable returns for investors.